In the following video, Motley Fool health-care analyst David Williamson takes a look at NPS Pharmaceuticals' (NASDAQ: NPSP) very bold move. This small company has just bought back the worldwide rights to both of its lead drugs, Gattex and Natpara, from the giant corporation Takeda. David tells investors how challenging it will be for the NPS Pharmaceuticals to take over management of worldwide sales of the two drugs, as well as just how big the potential rewards from this move could be.
This small biotech company just bet big.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid